| Autor: |
Szkultecka-Dębek M; Roche Polska Sp. z o.o., Warsaw, Poland., Walczak J; Arcana Institute, Cracow, Poland., Augustyńska J; Arcana Institute, Cracow, Poland., Miernik K; Arcana Institute, Cracow, Poland., Stelmachowski J; Arcana Institute, Cracow, Poland., Pieniążek I; Arcana Institute, Cracow, Poland., Obrzut G; Arcana Institute, Cracow, Poland., Pogroszewska A; Arcana Institute, Cracow, Poland., Paulić G; Roche Ltd, Zagreb, Croatia., Damir M; Roche Ltd, Zagreb, Croatia., Antolić S; Roche Ltd, Zagreb, Croatia., Tavčar R; University Psychiatric Clinic Ljubljana, Slovenia., Indrikson A; Roche Eesti OÜ, Tallinn, Estonia., Aadamsoo K; Psychiatry Clinic, North Estonia Medical Centre, Tallinn, Estonia., Jankovic S; Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia., Pulay AJ; Department of Psychiatry and Psychotherapy, Semmelweis University, Hungary., Rimay J; Roche (Magyarország) Kft, Budaörs, Hungary., Varga M; Roche (Magyarország) Kft, Budaörs, Hungary., Sulkova I; Roche Slovensko, s.r.o., Bratislava, Slovakia., Veržun P; Roche d.o.o. Slovenia, Ljubljana, Slovenia. |
| Abstrakt: |
Aim: To gather and review data describing the epidemiology of schizophrenia and clinical guidelines for schizophrenia therapy in seven Central and Eastern European countries, with a focus on negative symptoms. Methods : A literature search was conducted which included publications from 1995 to 2012 that were indexed in key databases. Results : Reports of mean annual incidence of schizophrenia varied greatly, from 0.04 to 0.58 per 1,000 population. Lifetime prevalence varied from 0.4% to 1.4%. One study reported that at least one negative symptom was present in 57.6% of patients with schizophrenia and in 50-90% of individuals experiencing their first episode of schizophrenia. Primary negative symptoms were observed in 10-30% of patients. Mortality in patients with schizophrenia was greater than in the general population, with a standardized mortality ratio of 2.58-4.30. Reasons for higher risk of mortality in the schizophrenia population included increased suicide risk, effect of schizophrenia on lifestyle and environment, and presence of comorbidities. Clinical guidelines overall supported the use of second-generation antipsychotics in managing negative symptoms of schizophrenia, although improved therapeutic approaches are needed. Conclusion : Schizophrenia is one of the most common mental illnesses and poses a considerable burden on patients and healthcare resources alike. Negative symptoms are present in many patients and there is an unmet need to improve treatment offerings for negative symptoms beyond the use of second-generation antipsychotics and overall patient outcomes. |
